Want to see DE:B8FK full AI Analyst Report?
B8FK Stock Chart & Stats
€2.53
€0.02(0.90%)
At close: 4:00 PM EST
€2.53
€0.02(0.90%)
Day’s Range― - ―
52-Week Range€2.21 - €5.10
Previous CloseN/A
Volume104.00
Average Volume (3M)2.74K
Market Cap
€17.62M
Enterprise Value€11.99M
Total Cash (Recent Filing)€3.08M
Total Debt (Recent Filing)€1.15M
Price to Earnings (P/E)―
Beta0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,076,862
10 Day Avg. Volume2,482
30 Day Avg. Volume2,739
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.99
Price to Sales (P/S)1.12
P/FCF Ratio-3.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAn approximately 83% gross margin indicates that Biofrontera’s products retain substantial economic value after direct costs. If revenue scales, this margin structure could provide meaningful operating leverage and support reinvestment in commercialization, regulatory access, and clinician adoption.
Conservative LeverageVery low leverage limits the immediate burden of interest and debt repayment on the business. This gives Biofrontera greater financial flexibility than a highly indebted peer if it needs to fund commercialization, absorb losses, or pursue growth while profitability remains weak.
Recurring PDT Product ModelThe combination of an installed PDT equipment base and recurring Ameluz gel usage creates a repeat-purchase element in the business model. Continued clinical adoption can therefore build consumable demand over time, rather than relying only on one-time device sales.
Bears Say
Volatile Revenue BaseThe sharp post-2023 revenue decline and limited 2025 recovery show that commercial performance has not yet become consistent. Such volatility makes planning and fixed-cost absorption more difficult, and it limits confidence that the high gross margin can translate into durable earnings.
Persistent Net LossesOngoing operating and net losses indicate that product-level profitability is not yet sufficient to cover the company’s broader cost base. Unless revenue expands or expenses fall materially, continued losses can consume equity and restrict the resources available for sustained commercial investment.
Ongoing Cash BurnRepeated negative operating and free cash flow show that the core business is consuming cash rather than self-funding. Persistent burn increases reliance on future revenue improvement or external financing, which can constrain strategic flexibility if the turnaround takes longer than expected.
Biofrontera News
B8FK FAQ
What was Biofrontera AG’s price range in the past 12 months?
Biofrontera AG lowest stock price was €2.21 and its highest was €5.10 in the past 12 months.
What is Biofrontera AG’s market cap?
Biofrontera AG’s market cap is €17.62M.
When is Biofrontera AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biofrontera AG’s earnings last quarter?
Currently, no data Available
Is Biofrontera AG overvalued?
According to Wall Street analysts Biofrontera AG’s price is currently Overvalued.
Does Biofrontera AG pay dividends?
Biofrontera AG does not currently pay dividends.
What is Biofrontera AG’s EPS estimate?
Biofrontera AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofrontera AG have?
Biofrontera AG has 6,076,862 shares outstanding.
What happened to Biofrontera AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biofrontera AG?
Currently, no hedge funds are holding shares in DE:B8FK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biofrontera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-127.78%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biofrontera AG
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
Technical Analysis
Eckert & Ziegler Strahlen und Medizintechnik
―
Evotec
―
Merck KGaA
―
Heidelberg Pharma AG
―
Dermapharm Holding SE
―